Group One Trading’s Can-Fite BioPharma American Depositary Shares CANF Stock Holding History

Group One Trading’s Portfolio CANF Stock Details CANF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-1	Closed	-$5K	–	4431
2016 Q3	$5K	Hold	1	–	–	﹤0.01%	4203
2016 Q2	$5K	Hold	1	–	–	﹤0.01%	4263
2016 Q1	$6K	Hold	1	–	–	﹤0.01%	4148
2015 Q4	$6K	Buy	+1	New	+$10.1K	﹤0.01%	4322

Other funds holding CANF

TAM

Taylor Asset Management Toronto, Ontario, Canada $154M AUM 10.32% 1-Year Est. Return

Menta Capital San Francisco, California $236M AUM 6.6% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Group One Trading's CANF Position: Q4 2016 in Review

Group One Trading sold out of Can-Fite BioPharma American Depositary Shares (CANF) in Q4 2016, closing a stake of 1 share — an estimated $5K sold.

Group One Trading first reported a position in CANF in Q4 2015 and held it in 4 quarters. The position peaked at $6K in Q1 2016. 6 funds tracked by Wall St. Rank hold CANF as of Q4 2016.

Group One Trading reported no remaining Can-Fite BioPharma American Depositary Shares position as of Q4 2016 after selling out during the quarter.
Group One Trading sold 1 Can-Fite BioPharma American Depositary Shares share in Q4 2016, an estimated $5K.
Group One Trading first reported a position in Can-Fite BioPharma American Depositary Shares in Q4 2015 and held it in 4 quarters.
Group One Trading's Can-Fite BioPharma American Depositary Shares position peaked at $6K in Q1 2016.
6 funds tracked by Wall St. Rank held Can-Fite BioPharma American Depositary Shares as of Q4 2016.

Based on Group One Trading's 13F filing for Q4 2016, filed 15 Feb 2017.